IntegriChain delivers the life science industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, managed services and expert advisors to power their operations and harness the value of their channel, patient and payer data.
View all products
From the first launch to ongoing market access execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We are the data and application backbone for market access departments of Life Sciences manufacturers, enabling them to accelerate their commercialization process, digitalize their operations, and get therapies to patients faster.
Solutions overview
To ensure you get the most out of your access and commercialization investment, IntegriChain provides a complete set of professional Advisory and Systems Integration Services designed to further your business and success.
Services overview
IntegriChain provides wide array of resources to help you navigate your journey to market access success.
Resources overview
We help all stakeholders in the life sciences industry drive access. We do this through our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts and pricing, gross-to-net, channel, and patient services – unlocking strategic payer, provider, pharmacy and patient access insights for our life sciences customers.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, Market Access experts, analysts, technologies, and advisory professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
The need for the type of accountability provided by order management technology has never been greater. Price Transparency legislation passed in a handful of states in 2017, including California. Additional states are working on their own bills. These laws have the potential to encourage price speculation. At the same time, the opioid epidemic has grown into a full-scale public health crisis and has placed the pharmaceutical industry under the microscope.
In this webinar, we’ll demonstrate how effective order management can limit a manufacturer’s susceptibility to price speculation and serve as a safeguard against suspicious orders of highly-regulated, controlled drugs.
Melissa O’Neal, Segment Leader, Distribution, is the presenter for Controlling Risks through Order Management: Addressing Price Transparency Laws and the Opioid Crisis.
